Perspective Therapeutics, Inc.
CATX$551.72B
Mega CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSEATTLE138 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CATX News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
[203Pb]VMT-α-NET
Neuroendocrine Tumors Unresectable
[203Pb]VMT01
Recurrent Melanoma (Skin)
[203Pb]Pb-PSV359
Pancreatic Ductal Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
[203Pb]VMT-α-NET | Phase 2 | Neuroendocrine Tumors Unresectable | - | - |
[203Pb]VMT01 | Phase 2 | Recurrent Melanoma (Skin) | - | - |
[203Pb]Pb-PSV359 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply